|

Neurocognitive Risks in Children With Solid Tumors

RECRUITINGSponsored by Gustave Roussy, Cancer Campus, Grand Paris
Actively Recruiting
SponsorGustave Roussy, Cancer Campus, Grand Paris
Started2014-10-01
Est. completion2025-09
Eligibility
Healthy vol.Accepted

Summary

The survival rate of children with cancer has improved significantly in recent years thanks to the progress of different therapies. The neurocognitive sequelae related to treatments and illness are more or less well known. Four factors seem to be associated with neurocognitive sequelae: treatment, the tumor itself, environmental factors like the socio-economic status of parents and biological factors. Main purpose of the study is to establish a score to assess the risk of neurocognitive sequelae in these children based on these factors (treatment, tumor, and environmental factors)

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Patient aged 6 to 16 years and 11 months during the study period
* Type of pathology: solid tumor
* Place of treatment and follow-up: Gustave Roussy
* Minimum time from the end of the initial treatment:
* For patients who have not received treatment with methotrexate: 6 months
* For patients being treated with methotrexate: none
* Obtaining the non-opposition of parents / legal representatives
* Affiliation to a social security scheme.

Exclusion Criteria:

* Patients with other pathologies associated with mental retardation (autism, genetic syndrome ...)
* Patients lost to follow-up
* Deceased patients
* Patients treated for a pathology whose prognosis is involved in the very short term (infiltrating glioma of the brainstem, recurrence of the pathology during treatment)
* Non-French speaking patients

Conditions2

CancerSolid Tumor in Children

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.